Last reviewed · How we verify
NCT03690193: KDRAFT
Feasibility and Efficacy of the Ketogenic Diet in Alzheimer's Disease
Completed
NA
Last updated 1 October 2018
What this trial tests
NA trial testing Ketogenic Diet in Alzheimer Disease in 15 participants. Completed in 6 January 2017.
Timeline
3 December 2013
Primary endpoint
6 January 2017
6 January 2017
6 January 2017
Quick facts
| Lead sponsor | University of Kansas Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 3 December 2013 |
| Primary completion | 6 January 2017 |
| Estimated completion | 6 January 2017 |
Drugs / interventions tested
- Ketogenic Diet — full drug profile →
Conditions studied
- Alzheimer Disease — all drugs for Alzheimer Disease →
Sponsor
University of Kansas Medical Center
Who can join
Eligibility, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the KDRAFT study is to assess the feasibility and preliminary cognitive efficacy of a ketogenic diet therapy in patients with Alzheimer's disease.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing.
Cunnane SC, Trushina E, Morland C, Prigione A, et al · · 2020 · cited 774× · PMID 32709961 · DOI 10.1038/s41573-020-0072-x -
FGF6 and FGF9 regulate UCP1 expression independent of brown adipogenesis.
Shamsi F, Xue R, Huang TL, Lundh M, et al · · 2020 · cited 90× · PMID 32184391 · DOI 10.1038/s41467-020-15055-9 -
Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention.
Peng Y, Gao P, Shi L, Chen L, et al · · 2020 · cited 84× · PMID 32050773 · DOI 10.1089/ars.2019.7763 -
p62-Nrf2-p62 Mitophagy Regulatory Loop as a Target for Preventive Therapy of Neurodegenerative Diseases.
Gureev AP, Sadovnikova IS, Starkov NN, Starkov AA, et al · · 2020 · cited 47× · PMID 33198234 · DOI 10.3390/brainsci10110847 -
An Experimental Ketogenic Diet for Alzheimer Disease Was Nutritionally Dense and Rich in Vegetables and Avocado.
Taylor MK, Swerdlow RH, Burns JM, Sullivan DK. · · 2019 · cited 35× · PMID 30931426 · DOI 10.1093/cdn/nzz003 -
Non-drug Therapies for Alzheimer's Disease: A Review.
Li X, Ji M, Zhang H, Liu Z, et al · · 2023 · cited 27× · PMID 36376734 · DOI 10.1007/s40120-022-00416-x -
Ketone body metabolism and cardiometabolic implications for cognitive health.
Fulghum K, Salathe SF, Davis X, Thyfault JP, et al · · 2024 · cited 11× · PMID 40093558 · DOI 10.1038/s44324-024-00029-y
Verify or expand the search:
- PubMed search for NCT03690193
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ketogenic Diet
Trials testing the same drug.
- NCT07121894 — Ketogenic Intervention for Bipolar Depression · NA · recruiting
- NCT06894004 — Mechanism of Ketogenic Diet-Induced Hypercholesterolemia · NA · recruiting
- NCT06515912 — Ketogenic Diet in Healthy Adults With Differing BMI · NA · completed
- NCT06503809 — Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes · NA · recruiting
- NCT06325644 — Well-Formulated Ketogenic Diet Polycystic Kidney Disease · NA · recruiting
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
- NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
- NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
- NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
- NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other University of Kansas Medical Center trials
Trials by the same sponsor.
- NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
- NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
- NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03690193 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
- Last refreshed: 1 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03690193.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing